Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey

ŞAHAN, Ceyda; PEKEL, Özlem; KORKMAZ, Eren; GÜLER, Ercan; CEYLAN, ALI; ÜNAL, Belgin; YILMAZ, Tuba Sevim; SÖZMEN, Kaan

Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey

Kaan SÖZMEN, (İl Halk Sağlığı Müdürlüğü, İzmir, Türkiye)

Özlem PEKEL, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye)

Tuba Sevim YILMAZ, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye)

Ceyda ŞAHAN, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye)

Ali CEYLAN, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye)

Ercan GÜLER, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye)

Eren KORKMAZ, (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye)

Belgin ÜNAL (Dokuz Eylül Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, İzmir, Türkiye)

The Anatolian Journal of Cardiology

2 1

Yıl: 2015 Cilt: 15 Sayı: 4 Sayfa Aralığı: 325 - 333 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey

Öz:

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analy- sis of population health data. Lancet 2006; 367: 1747-57. [CrossRef]
2. Dinç G, Sözmen K, Gerçeklioğlu G, Arık H, Critchley J, Ünal B. Decreasing trends in cardiovascular mortality in Turkey between 1988 and 2008. BMC Public Health 2013; 13: 896. [CrossRef]
3. WHO. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization 2011.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245. [CrossRef]
5. Çakır B, Çalışkan Z, Ergun H, Erol C, Gümüşel B, Tokgözoğlu L, et al. PCV34 The Economic Cost of Acute Coronary Syndrome in Turkey. Value in Health 2012; 15: A368. [CrossRef]
6. Ünal B, Sözmen K, Uçku R, Ergör G, Soysal A, Baydur H, et al. High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anatol J Cardiol 2013; 13: 9-17.
7. Onat A, Şenocak MS, Şurdum-Avcı G, Örnek E. Prevalence of coronary heart disease in Turkish adults. Int J Cardiol 1993; 39: 23-31. [CrossRef]
8. TURKSTAT. Turkish Health Survey 2010. Ankara: Turkish Statistical Institute 2012.
9. Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, et al. Heart failure prevalence and predictors in Turkey: HAPPY study. Turk Kardiyol Dern Ars 2012; 40: 298-308. [CrossRef]
10. Fak AS, Küçükoğlu MS, Fak NA, Demir M, Ağır AA, Demirtaş M, et al. Expert panel on cost analysis of atrial fibrillation. Anatol J Cardiol 2013; 13: 26-38.
11. Taylor MJ, Scuffham PA, McCollam PL, Newby DE. Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr Med Res Opin 2007; 23: 495-503. [CrossRef]
12. MoH. General Directorate of Pharmaceuticals and Pharmacy Price List. 2013 [cited 11.05.2013]; Available from: http://www.iegm. gov.tr/Default.aspx?sayfa=fiyat_listesi.
13. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348-53. [CrossRef]
14. Moran JL, Solomon PJ, Peisach AR, Martin J. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract 2007; 13: 381-9. [CrossRef]
15. Ergin A, Eryol NK, Ünal S, Deliceo A, Topsakal R, Seyfeli E. Epidemiological and pharmacological profile of congestive heart failure at Turkish academic hospitals. Anatol J Cardiol 2004; 4: 32-8.
16. The Infrastructure Development for Strengthening and Restructuring of Health Services Financial Management Project. Ankara: Hacettepe University 2007.
17. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospital- ized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-36. [CrossRef]
18. OECD. Health at a Glance 2011: OECD Indicator: OECD Publishing 2011.
19. MoH. Health Statistics Yearbook 2011: Ministry of Health of Turkey 2012.
20. EU. EUROSTAT, Population and Social Conditions. 2011; Available from: http://epp.eurostat.ec.europa.eu/portal/page/portal/statis- tics/search_database.
21. Aslan BU, Karcıoğlu O, Aslan O, Ayrık C, Kulaç C, Güneri S. Does the short-term mortality differ between men and women with first acute myocardial infarction? Anatol J Cardiol 2002; 4: 284-90.
22. Cook S, Walker A, Hügli O, Togni M, Meier B. Percutaneous coro- nary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clin Res Cardiol 2007; 96: 375-82. [CrossRef]
23. Bramkamp M, Radovanovic D, Erne P, Szucs TD. Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10.000 patients. Cardiovasc Drugs Ther 2007; 21: 389-98. [CrossRef]
24. Soekhlal RR, Burgers LT, Redekop WK, Tan SS. Treatment costs of acute myocardial infarction in the Netherlands. Neth Heart J 2013; 21: 230-5. [CrossRef]
25. Jaworski R, Jankowska EA, Ponikowski P, Banasiak W. Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study. Pol Arch Med Wewn 2012; 122: 599-607.
26. Krumholz HM, Chen J, Murillo JE, Cohen DJ, Radford MJ. Clinical correlates of in-hospital costs for acute myocardial infarction in patients 65 years of age and older. Am Heart J 1998; 135: 523-31. [CrossRef]
27. Moleerergpoom W, Kanjanavanit R, Jintapakorn W, Sritara P. Costs of payment in Thai acute coronary syndrome patients. J Med Assoc Thai 2007; 90 Suppl 1: 21-31.
28. Canpolat U, Aytemir K, Yorgun H, Hazırolan T, Kaya EB, Ateş AH, et al. Association of type 2 diabetes mellitus with coronary athero- sclerotic plaque burden and morphology measured by multidetec- tor computed tomography coronary angiography. Acta Cardiol 2012; 67: 71-7.
29. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29.863 patients in the US man- aged-care setting. Cardiovasc Diabetol 2009; 8: 53. [CrossRef]
30. Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myo- cardial infarction: mechanism of the smokers paradox from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26: 1222-9. [CrossRef]
31. Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR Jr. Effect of smoking status on the long-term outcome after successful percuta- neous coronary revascularization. N Engl J Med 1997; 336: 755-61. [CrossRef]
32. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265-71. [CrossRef]
33. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the pri- mary prevention of cardiovascular events: a summary of the evi- dence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161-72. [CrossRef]
34. Tiemann O. Variations in hospitalization costs for acute myocardial infarction - a comparison across Europe. Health Econ 2008; 17: S33-45. [CrossRef]
35. Tan SS, Bouwmans CA, Rutten FF, Hakkaart-van Roijen L. Update of the Dutch Manual for Costing in Economic Evaluations. Int J Technol Assess Health Care 2012; 28: 152-8. [CrossRef]
36. Tarride JE, Lim M, DesMeules M, Luo W, Burke N, OReilly D, et al. A review of the cost of cardiovascular disease. Can J Cardiol 2009; 25: e195-202. [CrossRef]
37. Schreyogg J, Tiemann O, Busse R. Cost accounting to determine prices: how well do prices reflect costs in the German DRG- system? Health Care Manag Sci 2006; 9: 269-79. [CrossRef]

APA	SÖZMEN K, PEKEL Ö, YILMAZ T, ŞAHAN C, CEYLAN A, GÜLER E, KORKMAZ E, ÜNAL B (2015). Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. , 325 - 333.
Chicago	SÖZMEN Kaan,PEKEL Özlem,YILMAZ Tuba Sevim,ŞAHAN Ceyda,CEYLAN ALI,GÜLER Ercan,KORKMAZ Eren,ÜNAL Belgin Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. (2015): 325 - 333.
MLA	SÖZMEN Kaan,PEKEL Özlem,YILMAZ Tuba Sevim,ŞAHAN Ceyda,CEYLAN ALI,GÜLER Ercan,KORKMAZ Eren,ÜNAL Belgin Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. , 2015, ss.325 - 333.
AMA	SÖZMEN K,PEKEL Ö,YILMAZ T,ŞAHAN C,CEYLAN A,GÜLER E,KORKMAZ E,ÜNAL B Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. . 2015; 325 - 333.
Vancouver	SÖZMEN K,PEKEL Ö,YILMAZ T,ŞAHAN C,CEYLAN A,GÜLER E,KORKMAZ E,ÜNAL B Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. . 2015; 325 - 333.
IEEE	SÖZMEN K,PEKEL Ö,YILMAZ T,ŞAHAN C,CEYLAN A,GÜLER E,KORKMAZ E,ÜNAL B "Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey." , ss.325 - 333, 2015.
ISNAD	SÖZMEN, Kaan vd. "Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey". (2015), 325-333.

APA	SÖZMEN K, PEKEL Ö, YILMAZ T, ŞAHAN C, CEYLAN A, GÜLER E, KORKMAZ E, ÜNAL B (2015). Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. The Anatolian Journal of Cardiology, 15(4), 325 - 333.
Chicago	SÖZMEN Kaan,PEKEL Özlem,YILMAZ Tuba Sevim,ŞAHAN Ceyda,CEYLAN ALI,GÜLER Ercan,KORKMAZ Eren,ÜNAL Belgin Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. The Anatolian Journal of Cardiology 15, no.4 (2015): 325 - 333.
MLA	SÖZMEN Kaan,PEKEL Özlem,YILMAZ Tuba Sevim,ŞAHAN Ceyda,CEYLAN ALI,GÜLER Ercan,KORKMAZ Eren,ÜNAL Belgin Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. The Anatolian Journal of Cardiology, vol.15, no.4, 2015, ss.325 - 333.
AMA	SÖZMEN K,PEKEL Ö,YILMAZ T,ŞAHAN C,CEYLAN A,GÜLER E,KORKMAZ E,ÜNAL B Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. The Anatolian Journal of Cardiology. 2015; 15(4): 325 - 333.
Vancouver	SÖZMEN K,PEKEL Ö,YILMAZ T,ŞAHAN C,CEYLAN A,GÜLER E,KORKMAZ E,ÜNAL B Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. The Anatolian Journal of Cardiology. 2015; 15(4): 325 - 333.
IEEE	SÖZMEN K,PEKEL Ö,YILMAZ T,ŞAHAN C,CEYLAN A,GÜLER E,KORKMAZ E,ÜNAL B "Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey." The Anatolian Journal of Cardiology, 15, ss.325 - 333, 2015.
ISNAD	SÖZMEN, Kaan vd. "Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey". The Anatolian Journal of Cardiology 15/4 (2015), 325-333.